Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
24.1M
-
Shares change
-
-2.96M
-
Total reported value, excl. options
-
$223M
-
Value change
-
-$73.1M
-
Put/Call ratio
-
3.22
-
Number of buys
-
48
-
Number of sells
-
-38
-
Price
-
$9.26
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q1 2021
107 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q1 2021.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.1M shares
of 66.6M outstanding shares and own 36.17% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (2.94M shares), Corriente Advisors, LLC (2.79M shares), Avidity Partners Management LP (2.45M shares), CAXTON CORP (2.11M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.78M shares), VANGUARD GROUP INC (1.57M shares), CITADEL ADVISORS LLC (1.3M shares), Artal Group S.A. (750K shares), TWO SIGMA INVESTMENTS, LP (725K shares), and Octagon Capital Advisors LP (650K shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.